Author Archive

New Pugatch Consilium Study Shows How Countries Can Develop Biotech Industry

Posted by:

A Pugatch Consilium study released today commissioned by the Biotechnology Innovation Organization (BIO) highlights strategies, policies and best practices that have been successful in creating an environment in which biotechnology innovation can flourish around the world.

The fifth edition of the Building the Bioeconomy report shows the correlation between economies with pro-innovation policy frameworks and those achieving strong biotechnology outputs. By examining 28 different indicators ranging from public policy inputs to biotechnology outputs, the report provides a full and detailed ...

Continue Reading →
0

Why IP Incentives Matter for Life Sciences Innovation – In Europe and Beyond

Posted by:

Why IP incentives matter for life sciences innovation – In Europe and Beyond

Pugatch Consilium is today releasing a new report – A Critical Incentive – Not a Barrier! How IP incentives spur biopharmaceutical innovation and the creation of new health technologies.

This report examines the importance of IP based incentives to biopharmaceutical innovation and the development of new medicines and medical technologies.

This analysis could not be more timely. In Europe, for example, the EU Commission is seriously considering ways to ...

Continue Reading →
0

Debunking the IP and Access to Medicines Myth Once and For All

Posted by:

Pugatch Consilium is today releasing the report Unlocking Global Health Strengthening Availability of Essential Medicines by Enhancing Healthcare Financing and Reducing Supply Chain Costs.

This report examines a common misperception in the international community: that patents and IP incentives block access to medicines.

 

An age-old debate: Patents and access

Discussions over the impact – positive or negative; rarely neutral – that IP rights have had and continue to have on the creation and dissemination of new ideas and commercial products is ...

Continue Reading →
0

To SPC or not to SPC…

Posted by:

Does the EU Commission really think weakening IP incentives for biopharmaceutical innovation in Europe is going to create more jobs and economic activity?

by Dr David Torstensson, Partner, Pugatch Consilium

As an industry the research-based biopharmaceutical sector is one of Europe’s biggest success stories. Companies like Novartis, Roche, Sanofi Aventis, Novo Nordisk, AstraZeneca and GSK are some of the largest, most innovative and successful research-based biopharmaceutical companies in the world. Not only do these companies have a long track record of producing ...

Continue Reading →
0

Unintended Consequences

Posted by:

Pugatch Consilium releases new study on the negative economic consequences of an SPC export exemption in Europe

Today Pugatch Consilium releases UNINTENDED CONSEQUENCES: How introducing a manufacturing and export exemption to supplementary protection certificates would weaken global standards of IP protection and result in direct losses to Europe’s research-based biopharmaceutical industry.

The study (which is also available via the Social Science Research Network, SSRN) models the economic impact an SPC manufacturing and export exemption would have on the European and global research-based ...

Continue Reading →
0

Building a Bioeconomy: A how-to guide

Posted by:

New study shows how countries can succeed in developing and building their biotech capabilities

A new study by international research consultancy Pugatch Consilium (commissioned by the Biotechnology Industry Organization) examines those national innovation strategies, policies and best practices that have been successful in creating an environment in which biotechnologies and biotechnological innovation can flourish.

2017 marks the fourth edition of the Building the Bioeconomy series of papers examining national biotechnology industrial policies. This year’s edition includes 26 countries from all major regions ...

Continue Reading →
0

Professor Meir Pugatch and U.S. Chamber of Commerce President Tom Donohue launch new fifth edition of the U.S. Chamber of Commerce’s International IP Index

Posted by:

Professor Meir Pugatch spoke together with Tom Donohue (President and CEO of the U.S. Chamber of Commerce), David Hirschmann (President and CEO of the U.S. Chamber of Commerce Global Intellectual Property Center) and former Director of the United States Patent and Trademark Office, David Kappos, at the launch of the fifth edition of the U.S. Chamber’s International IP Index in Washington D.C earlier this week.

Continue Reading →

0

Pugatch Consilium Releases New Study on Regulatory Standards for Approval of Generic Medicines

Posted by:

Today Pugatch Consilium releases Generic drugs appraisal and approval: departing from the ‘one-size-fits-all’ approach.

Generic medicines – follow-on versions of off-patent innovative medicines – are designed to be interchangeable to the innovative reference product. As more sophisticated and complex medicines are developed, securing the safe and effective use of their follow-on products becomes increasingly challenging.

This report zeroes in on the existing gaps and challenges within the ‘one-size-fits-all’ model of generic drugs approval vis-à-vis two particularly complex drugs: Narrow Therapeutic Index (NTI ...

Continue Reading →
0

New Pugatch Consilium report finds Colombia could see over 100 new clinical trials and up over $450 million in economic gains per year with policy reform

Posted by:

Today Pugatch Consilium releases Challenges and Opportunities – Developing the Biotechnology Sector in Colombia.

The purpose of this report is to, firstly, give a comparative overview of the biotechnology sector in Colombia and, secondly, provide an estimate of how an improvement to Colombia’s policy environment can result in higher biotechnology outputs including rates of biomedical FDI and clinical trials.

The report maps the current policy environment as it relates to biotechnology in Colombia and gives a detailed comparison on key major biotechnology ...

Continue Reading →
0

Pugatch Consilium releases new edition of Building the Bioeconomy – Shows how economies that are successful in building a high-tech biotechnology capacity put the right enabling policies in place

Posted by:

Commissioned by the Biotechnology Industry Organization and authored by Pugatch Consilium this series of reports seek to provide an overview of those national innovation strategies, policies and best practices that have been successful in creating an environment in which biotechnologies and biotechnological innovation can flourish.

 

This year Building the Bioeconomy has grown from thirteen economies to sixteen, adding Colombia, Israel and Japan. As in previous editions the sample of economies is geographically and economically diverse with a mix of high-income mature ...

Continue Reading →
0
Page 1 of 4 1234